Meloxicam

Chronic inflammatory joint diseases such as osteoarthritis and rheumatoid arthritis have long troubled more than 500 million patients worldwide. The treatment of such diseases requires not only the relief of pain symptoms, but also the control of inflammatory progression while reducing the risk of gastrointestinal adverse reactions. Meloxicam is an enolic acid class of non-steroidal anti-inflammatory drug (NSAID), which blocks the synthesis of prostaglandins by selectively inhibiting cyclooxygenase-2 (COX-2). Compared with non-selective NSAIDs, it greatly reduces the risk of adverse reactions such as gastrointestinal ulcers and bleeding. It is widely used clinically for the symptomatic treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis, and can also be used for the short-term relief of acute pain. The applicable population covers adults and adolescent patients with rheumatoid arthritis over 12 years old.

The global meloxicam market size is stable at around USD 1.2 billion, with a compound annual growth rate of approximately 2.8%. The growth momentum mainly comes from the rising prevalence of osteoarthritis and the release of demand for chronic disease treatment in emerging markets. In terms of the domestic market, the sales of meloxicam at public hospital terminals in 2023 were approximately RMB 720 million, of which oral dosage forms accounted for more than 85%. At present, there are more than 30 domestic manufacturers of approved meloxicam generic drugs, and 17 product specifications have passed the consistency evaluation. After centralized procurement, the price in the public market has dropped by more than 60%, and the share of domestic manufacturers in the API supply side has reached more than 90%, gradually replacing the original research imported raw materials.

The original research enterprise of meloxicam is Boehringer Ingelheim, and the original research trade name is "Mobic". Its core compound patent expired globally in 2004, and the expiration date of the preparation patent in China is 2009. The main dosage forms approved by the original research include 7.5mg and 15mg tablets, as well as 15mg/1.5ml injection, which have been included in the Reference Preparation Catalogue of Chemical Drugs of China NMPA and the FDA Reference Preparation Catalogue. Up to now, there are 38 meloxicam registration records on the API registration platform of China CDE, of which 29 are in status "A" (marketable). The domestically approved meloxicam preparations cover multiple dosage forms such as tablets, capsules, suppositories and injections, and the available specifications cover the needs of all clinical scenarios. (Data as of June 2025, please refer to the official CDE website for the latest information)

CATO provides a full set of meloxicam impurity reference standards. The products fully meet the compliance requirements of multiple regulatory systems such as Chinese Pharmacopoeia and FDA. Most products are in regular stock. Spot orders placed before 16:00 can be shipped on the same day, which can fully meet the reference standard needs of pharmaceutical enterprises in R&D, quality research and production processes.